Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-29T07:30:09.563Z Has data issue: false hasContentIssue false

Chapter 2 - Botulinum Neurotoxin

History of Clinical Development

Published online by Cambridge University Press:  02 November 2023

By
Daniel Truong ,
Deepmala Nandanwar  and
Mark Hallett
Edited by
Daniel Truong ,
Dirk Dressler ,
Mark Hallett ,
Christopher Zachary  and
Mayank Pathak
Daniel Truong
Affiliation:
University of California, Riverside
Dirk Dressler
Affiliation:
Hannover Medical School
Mark Hallett
Affiliation:
National Institutes of Health (NIH)
Christopher Zachary
Affiliation:
University of California, Irvine
Mayank Pathak
Affiliation:
Truong Neuroscience Institute
Get access

Summary

In 1980, Alan B Scott published the use of botulinum neurotoxin type A by injection into extraocular muscles for treatment of strabismus. Use in blepharospasm was published in 1985, and cervical dystonia in 1986, followed by hemifacial spasm and other dystonias, including spasmodic dysphonia, hand dystonia, and conditions such as limb spasticity.

Formulations of neurotoxin type A worldwide include: Botox/onabotulinumtoxinA, Dysport/abobotulinumtoxinA, Xeomin/incobotulinumtoxinA, and a Chinese product marketed under various brand names in Asia. Botulinum neurotoxin type B is marketed as Neurobloc/Myobloc, or rimabotulinumtoxinB. PrabotulinumtoxinA and daxibotuinumtoxinA-Ianm are type A toxins under development.

Keywords

StrabismusAlan B. Scottobotulinum neurotoxinoculinumblepharospasmcervical dystoniahemifacial spasmdystoniaBotoxonabotulinumtoxinANeuroBlocMyoblocrimabotulinumtoxinBXeominincobotulinumtoxinADysport abobotulinumtoxinA prabotulinumtoxinANeuronoxMeditoxinoxibotulinumtoxinA,daxibotulinumtoxinA-IanmDAXXIFY
Type
Chapter
Information
Manual of Botulinum Toxin Therapy , pp. 9 - 12
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Beer, K.R., Shamban, AT, Avelar, RL, Gross, JE, Jonker, A (2019). Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg, 45(11), 1381–93.CrossRefGoogle ScholarPubMed
Blitzer, A, Brin, MF, Fahn, S, Lange, D, Lovelace, RE (1986). Botulinum toxin (BOTOX) for the treatment of “spastic dysphonia” as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope, 96, 1300–1.Google Scholar
Brin, MF, Fahn, S, Moskowitz, C et al. (1987). Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord, 2, 237–54.CrossRefGoogle ScholarPubMed
Brooks, V (2001). Vernon Brooks. In Squire, LR (ed.) The History of Neuroscience in Autobiography, Vol. 3. New York: Academic Press, pp. 76–116.Google Scholar
Choudhury, S, Baker, M, Chatterjee, S, Kumar, H (2021). Botulinum toxin: an update on pharmacology and newer products in development. Toxins 2021, 13(1), 58; https://doi.org/10.3390/toxins13010058Google ScholarPubMed
Cohen, LG, Hallett, M, Geller, BD, Hochberg, F (1989). Treatment of focal dystonias of the hand with botulinum toxin injections. J Neurol Neurosurg Psychiatry, 52, 355–63.Google Scholar
Das, TK, Park, DM (1989). Effect of treatment with botulinum toxin on spasticity. Postgrad Med J, 65, 208–10.CrossRefGoogle ScholarPubMed
Drachman, DB (1964). Atrophy of skeletal muscle in chick embryos treated with botulinum toxin. Science, 145, 719–21.CrossRefGoogle ScholarPubMed
Dressler, D (2000). Botulinum Toxin Therapy. Stuttgart: Thieme-Verlag.Google ScholarPubMed
Dressler, D, Benecke, R (2006). Xeomin eine neue therapeutische Botulinum Toxin Typ A-Präparation. Akt Neurol, 33, 138–41.Google Scholar
Dressler, D, Benecke, R, Conrad, B (1989). Botulinum Toxin in der Therapie kraniozervikaler Dystonien. Nervenarzt, 60, 386–93.Google Scholar
Durham, PL, Cady, R, Cady, R (2004). Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache, 44, 35–42.Google Scholar
Elston, JS (1985). The use of botulinum toxin A in the treatment of strabismus. Trans Ophthalmol Soc UK, 104, 208–10.Google ScholarPubMed
Elston, JS, Lee, JP, Powell, CM, Hogg, C, Clark, P (1985). Treatment of strabismus in adults with botulinum toxin A. Br J Ophthalmol, 69, 718–24.Google Scholar
Frueh, BR, Felt, DP, Wojno, TH, Musch, DC (1984). Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol, 102, 1464–8.CrossRefGoogle ScholarPubMed
Fahn, S, List, T, Moskowitz, CB et al. (1985). Double-blind controlled study of botulinum toxin for blepharospasm. Neurology, 35(Suppl 1), 271.Google Scholar
Homann, CN, Wenzel, K, Kriechbaum, N et al. (2002). Botulinum Toxin: Die Dosis macht das Gift. Ein historischer Abriß. Nervenheilkunde, 73, 519–24.Google Scholar
Jankovic, J, Orman, J (1987). Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology, 37, 616–23.Google Scholar
Jeuveau package insert version 02/2019.Google Scholar
Lalli, G, Bohnert, S, Deinhardt, K, Verastegui, C, Schiavo, G (2003). The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol, 11, 431–7.CrossRefGoogle ScholarPubMed
Moore, P, Naumann, M (2003). Handbook of Botulinum Toxin Treatment, 2nd ed. Malden, MA: Blackwell Science.Google Scholar
Mauriello, JA Jr. (1985). Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology, 35, 1499–500.CrossRefGoogle ScholarPubMed
National Institutes of Health. (1991). National Institutes of Health Consensus Development Conference. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Statement, November 12–14, 1990. Arch Neurol, 48, 1294–8.Google Scholar
Rzany, BJ, Ascher, B, Avelar, R, Bergdahl, J, Bertucci, V et al. (2020). A multicenter, randomized, doubleblind, placebo-controlled, single-dose, phase iii, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J, 40(4), 413–29.Google ScholarPubMed
Roggenkamper, P (1986). [Blepharospasm treatment with botulinum toxin (follow-up).] Klin Monbl Augenheilkd, 189, 283–5.Google ScholarPubMed
Schantz, EJ (1994). Historical perspective. In Jankovic, J, Hallett, M (eds.) Therapy with Botulinum Toxin. New York: Marcel Dekker, pp. xxiii–xxvi.Google Scholar
Scott, AB (1980). Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology, 87(10), 1044–9.CrossRefGoogle ScholarPubMed
Scott, AB (1994). Foreword. In Jankovic, J, Hallett, M (eds.) Therapy with Botulinum Toxin. New York: Marcel Dekker, pp. vii–ix.Google Scholar
Scott, AB, Rosenbaum, A, Collins, CC (1973). Pharmacologic weakening of extraocular muscles. Invest Ophthalmol, 12, 924–7.Google ScholarPubMed
Scott, AB, Kennedy, RA, Stubbs, HA (1985). Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol, 103(3), 347–50.CrossRefGoogle ScholarPubMed
Simpson, LL (1979). The action of botulinal toxin. Rev Infect Dis, 1, 656–62.CrossRefGoogle ScholarPubMed
Stell, R, Thompson, PD, Marsden, CD (1988). Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry, 51(7), 920–3.CrossRefGoogle ScholarPubMed
Truong, DD, Jost, WH (2006). Botulinum toxin: clinical use. Parkinsonism Relat Disord, 12, 331–55.CrossRefGoogle ScholarPubMed
Troung, DD, Rontal, M, Rolnick, M, Aronson, AE, Mistura, K (1991). Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope, 101, 630–4.Google ScholarPubMed
Tsui, JK, Eisen, A, Mak, E et al. (1985). A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci, 12, 314–16.CrossRefGoogle ScholarPubMed
Tsui, JK, Eisen, A, Stoessl, AJ, Calne, S, Calne, DB (1986). Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, 2(8501), 245–7.Google ScholarPubMed
Welch, MJ, Purkiss, JR, Foster, KA (2000). Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon, 38, 245–58.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×